Lymphoma

Juno Therapeutics has reopened the phase II clinical trial (ROCKET trial) of JCAR015 in adult patients with B-cell acute lymphoblastic leukemia following three deaths.

The advantage of treating low- or intermediate-risk APL with ATRA plus arsenic trioxide appears to increase over time, according to results of the APL0406 trial.

Results of a single-center analysis indicated that patients aged 80 or older with DLBCL had superior outcomes with anthracycline-based therapies.

Combination treatment with obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly delayed disease progression in patients with indolent non-Hodgkin lymphoma refractory to rituximab.

The targeted therapy drug everolimus may be safely combined with R-CHOP in newly diagnosed, untreated diffuse large B-cell lymphoma.

Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.

Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.

Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have recently discovered how gene mutations keep blood stem cells from maturing, leading to the development of AML.

Dietary, pet, and social contact restrictions did not have any effect on infectious complications in children undergoing intensive treatment of acute myeloid leukemia.

A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.

Similar survival outcomes were seen in lymphoma patients who underwent related donor haploidentical HCT and HLA-matched sibling donor transplant.

The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.

Researchers published a study June 12, 2016, in the online issue of The New England Journal of Medicine that suggests progression-free survival and overall survival may both be longer with inotuzumab ozogamicin in ALL.

Patients with follicular lymphoma that responded to rituximab but whose disease later underwent histologic transformation were found to have worse outcomes and may benefit from autologous stem cell transplantation.

Patients with HIV-related lymphoma who underwent autologous hematopoietic cell transplant had good survival at 1 year, similar to patients without HIV.

Adding bortezomib to bendamustine/rituximab significantly improves complete remission rates in previously untreated high-risk follicular lymphoma, according to a new study.

This management guide covers the risk factors, screening, diagnosis, staging, and treatment of Hodgkin lymphoma.

Researchers at Weill Cornell Medicine recently published a study in Nature Communications explaining that the rate at which genetically mutated cancer cells grow may help explain why some CLL patients develop treatment resistance.

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

The US Food and Drug Administration (FDA) granted accelerated approval of nivolumab (Opdivo) based on overall response rate (ORR) in classical Hodgkin lymphoma patients.

The early 21st century has brought with it significant improvements in survival from most common hematologic malignancies for patients aged 65 years or older, but these increases still lag behind those of 50- to 59-year-olds.

Some patients with mantle cell lymphoma may safely defer treatment for their disease, and, in fact, deferral of therapy was an independent predictor of overall survival.

Chronic myeloid leukemia patients had a significantly increased prevalence of prior malignancies and autoimmune disorders compared with the general population.

Blood transfusions play a key role in managing complications of acute promyelocytic leukemia (APL), involving unique blood product strategies.

The addition of pegylated interferon-ɑ2b to dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukemia patients.